![]() |
市場調查報告書
商品編碼
1734883
2032 年乳酸菌菌株市場預測:按類型、形態、最終用戶和地區進行的全球分析Lactobacillus Strains Market Forecasts to 2032 - Global Analysis By Type, Form, End User and By Geography |
根據 Stratistics MRC 的數據,預測期內全球乳酸菌菌株市場以 7.2% 的複合年成長率成長。
乳酸桿菌菌株是一種有益菌,常見於Kefir、德國酸菜和優格等發酵食品以及人體腸道。這些益生菌能夠增強免疫系統,抑制有害病原體的生長,並平衡腸道菌群,對維持消化器官系統健康至關重要。包括嗜酸乳桿菌、鼠李糖乳桿菌和乾酪乳桿菌在內的各種菌株都具有特殊特性,可提供各種健康益處,例如全面支持免疫功能、改善乳糖消化和減輕胃腸不適。此外,由於其在促進腸道健康和預防某些感染疾病方面的治療潛力,它們擴大被用於膳食補充劑和機能性食品中。
根據美國衛生研究院(NIH)的數據,約有390萬人(佔成年人口的1.6%)使用益生菌作為維護健康的一部分,其中乳酸桿菌菌株是最常服用的益生菌之一。
提高消費者對腸道健康的認知
消費者越來越意識到健康的腸道菌叢對維持整體健康的重要性。科學文獻、健康影響者和醫學專家指出,益生菌對免疫調節和消化器官系統平衡至關重要,這進一步增強了消費者的這種意識。乳酸桿菌菌株因其在預防腹瀉、增強營養吸收和減少腹脹方面的公認益處而廣受歡迎。此外,這些益生菌正透過補充劑和機能性食品積極地融入人們的日常飲食中,這推動了國際市場的穩定需求。
缺乏針對特定菌株的監管和標準化
儘管許多益生菌產品聲稱含有乳酸桿菌菌株,但其功效、適應症和效果往往不一致。不同地區的法律規範差異很大,並非所有國家都要求對特定菌株的健康聲明進行臨床檢驗。這導致全球益生菌標準缺乏統一性,給消費者帶來困惑。此外,缺乏針對特定菌株用途的鑑定和劑量指南,可能會損害消費者的信任,並限制科學先進配方的商業化。
益生菌物質的創造
藥用級益生菌研發的投資正在不斷增加,乳酸桿菌菌株不僅作為膳食補充劑銷售,還作為輔助治療劑銷售,包括用於治療細菌性陰道炎、發炎性腸道疾病(IBD) 和抗生素相關性腹瀉。此外,處方益生菌的出現以及證實菌株特異性功效的臨床研究,為希望利用乳酸桿菌菌株治療潛力的製藥和生物技術公司開闢了新的收益來源。
價格壓力大,市場競爭激烈
從跨國公司到本土補充劑品牌,眾多參與者的加入使得益生菌市場(包括乳酸菌菌株)競爭異常激烈。這導致了價格戰,尤其是在機能性食品和營養保健品行業。當品牌在價格而非品質和創新上競爭時,商品化就會出現,這會削弱菌株特定好處的獨特價值。此外,零售連鎖店中的自有品牌產品進一步削弱了高階製造商的定價能力,從而降低了其長期生存能力和盈利。
新冠疫情對乳酸菌市場產生了多方面的影響。由於消費者對免疫和腸道健康的關注度顯著提升,益生菌補充劑和含有乳酸菌的機能性食品的需求旺盛。疫情期間,超過43%服用補充劑的美國人增加了免疫支持產品的消費,從而提振了短期銷售。然而,市場也面臨供應鏈中斷、原料取得受限以及生產和分銷延遲等挑戰,尤其是對於需要冷藏的益生菌產品。此外,產品核可和臨床試驗也受到監管延遲的影響,這在一定程度上抑制了創新。
預計乳酸菌細分市場在預測期內將佔據最大佔有率
預計乳酸菌細分市場將在預測期內佔據最大市場佔有率。這種優勢可歸因於其在藥品、發酵乳製品和膳食補充劑中的廣泛應用,因為已被證實具有增強免疫力、促進腸道健康和幫助乳糖消化等益處。嗜酸乳桿菌是研究最多的益生菌菌株之一,它通常包含在多菌株配方中,並以其穩定性和與其他有益菌的兼容性而聞名。此外,嗜酸乳桿菌強大的臨床檢驗和適應性確保了其在成熟市場和新興市場的益生菌市場中持續佔據主導地位。
預計在預測期內,液體部分將以最高的複合年成長率成長。
預計液體益生菌市場將在預測期內實現最高成長率。這一成長主要源於對易飲用、高效益生菌補充劑日益成長的需求。由於生物利用度更高、攝取更方便,液體製劑尤其受到老年人和兒童的青睞。液體製劑也常用於動物飼料,有助於解釋該市場的快速成長。此外,隨著消費者偏好轉向更容易取得、功效更強的益生菌產品,液體市場預計將大幅成長。
預計亞太地區將在預測期內佔據最大的市場佔有率。這一領先地位的形成得益於許多因素,包括豐富的發酵食品文化遺產、日益增強的健康意識以及中國和印度等國人口的快速成長。富含益生菌的食品(如Kefir、泡菜和優格)日益普及,以及人們對其有益腸道健康的認知不斷提高,顯著增加了對乳酸菌產品的需求。此外,亞太地區是市場擴張的主要驅動力,該地區的本地生產商正在利用這一趨勢,推出尖端的益生菌配方。
預計北美地區在預測期內將出現最高的複合年成長率,這得益於注重健康的消費者數量增加以及人們對免疫和腸道健康益處的認知不斷加深。機能性食品的需求顯著成長,尤其是在千禧世代和老年人群體中,他們尋求預防性保健,這推動了這一成長。此外,該地區強大的醫療保健體系和良好的法規環境也進一步支持了乳酸菌菌株市場的成長。
According to Stratistics MRC, the Global Lactobacillus Strains Market is growing at a CAGR of 7.2% during the forecast period. Lactobacillus strains are a type of good bacteria that are frequently found in fermented foods like kefir, sauerkraut, and yogurt as well as in the human gut. By strengthening the immune system, preventing the growth of dangerous pathogens, and balancing the gut microbiota, these probiotic microbes are essential for preserving digestive health. Different strains, including Lactobacillus acidophilus, Lactobacillus rhamnosus, and Lactobacillus casei, have special qualities that support immune function overall, improve lactose digestion, and lessen gastrointestinal discomfort, among other health benefits. Moreover, their therapeutic potential in promoting gut health and preventing certain infections has led to an increasing exploration of their use in dietary supplements and functional foods.
According to data from the National Institutes of Health (NIH), probiotics are indeed used by approximately 3.9 million U.S. adults, which account for 1.6% of the adult population, as part of their wellness routines. Lactobacillus strains are among the most commonly consumed probiotics.
Growing awareness of gut health among consumers
The significance of a healthy gut microbiota in preserving general wellness is becoming more widely acknowledged by consumers. Scientific publications, health influencers, and medical professionals who advocate probiotics as crucial for immune modulation and digestive balance are driving this awareness. The well-established advantages of Lactobacillus strains, in particular, like preventing diarrhea, promoting nutrient absorption, and lessening bloating, have made them popular. Moreover, these probiotics are therefore being actively added to people's daily diets through supplements and functional foods, which is driving steady demand in international markets.
Absence of strain-specific regulation and standardization
Despite the fact that many probiotic products make the claim to contain Lactobacillus strains, labeling, potency, and efficacy are frequently inconsistent. There are significant regional differences in regulatory frameworks, and not all nations require clinical validation for health claims pertaining to particular strains. This prevents probiotic standards from being harmonized globally and causes consumers to become confused. Furthermore, if strain-specific applications lack required identification and dosage guidelines, consumer confidence may be damaged, and the commercialization of scientifically advanced formulations may be restricted.
Creation of probiotic substances
Investment in the creation of pharmaceutical-grade probiotics is rising, and Lactobacillus strains are being marketed as supplements to medical treatments as well as dietary supplements. Treatments for bacterial vaginosis, inflammatory bowel disease (IBD), antibiotic-associated diarrhea, and other conditions are among them. Moreover, the emergence of prescription probiotics and clinical studies confirming strain-specific effects opens up new revenue streams for pharmaceutical and biotech companies hoping to leverage Lactobacillus strains' therapeutic potential.
High levels of price pressure and market competition
The introduction of many players, from global firms to local supplement brands, has made the probiotic market-which includes Lactobacillus strains-extremely competitive. There are now price wars as a result, especially in the functional food and dietary supplement industries. The distinctive value of strain-specific benefits may be diminished as a result of commoditization, which occurs when brands compete on price rather than quality or innovation. Furthermore, private-label goods in retail chains further weaken premium manufacturers' pricing power, reducing their long-term viability and profitability.
The COVID-19 pandemic affected the market for Lactobacillus strains in a variety of ways. Probiotic supplements and functional foods that contain Lactobacillus strains are in high demand as a result of the substantial increase in consumer awareness of immunity and gut health. During the pandemic, more than 43 percent of Americans who take supplements increased their consumption of immune-supporting products, which increased short-term sales. But the market also had to contend with issues like disruptions in the supply chain, restricted access to raw materials, and production and distribution delays, especially for probiotic products that were refrigerated. Additionally, product approvals and clinical trials were impacted by regulatory slowdowns, which somewhat inhibited innovation.
The lactobacillus acidophilus segment is expected to be the largest during the forecast period
The lactobacillus acidophilus segment is expected to account for the largest market share during the forecast period. This dominance is ascribed to its extensive use in pharmaceuticals, fermented dairy products, and dietary supplements because of its proven advantages in enhancing immunity, promoting gut health, and facilitating lactose digestion. One of the most studied probiotic strains is Lactobacillus acidophilus, which is frequently found in multistrain formulations and is known for its stability and compatibility with other good bacteria. Moreover, Lactobacillus acidophilus's strong clinical validation and adaptability guarantee its sustained dominance in both established and developing probiotic markets.
The liquid segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the liquid segment is predicted to witness the highest growth rate. This expansion is mostly due to the growing need for easy-to-take and efficient probiotic supplements. Due to their improved bioavailability and ease of consumption, liquid formulations are especially well-liked by older adults and children. The liquid form is also frequently used in animal feed, which helps explain its quick market growth. Additionally, the liquid market is expected to grow significantly as consumer preferences change toward more readily available and powerful probiotic options, which will be in line with larger trends in health and wellness.
During the forecast period, the Asia Pacific region is expected to hold the largest market share. Numerous factors, such as a rich cultural legacy of fermented foods, increased health consciousness, and a rapidly expanding population in nations like China and India, are contributing to this leadership. The demand for Lactobacillus-based products has increased significantly as a result of the growing popularity of probiotic-rich foods like kefir, kimchi, and yogurt as well as growing awareness of the advantages for gut health. Furthermore, Asia Pacific is becoming a major force behind market expansion as local producers in the area are leveraging this trend by launching cutting-edge probiotic formulations.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by a rise in health-conscious consumers and growing knowledge of the advantages of immunity and gut health. The demand for functional foods has significantly increased, especially among millennials and older populations looking for preventive wellness options, which is driving this growth. Moreover, the market growth for Lactobacillus strains is further supported by the region's strong healthcare system and advantageous regulatory environment.
Key players in the market
Some of the key players in Lactobacillus Strains Market include Morinaga Milk Industry Co., Ltd., Chr. Hansen Holding A/S, Danone S.A, ADM (Archer-Daniels-Midland Company), Nestle S.A, Koninklijke DSM N.V., International Flavors & Fragrances Inc., Arla Foods Inc, Lallemand Inc., Yakult Honsha Co., Ltd., DowDuPont, Chobani LLC, Kerry Inc, Post Holdings Inc and Novozymes Inc.
In September 2024, Nestle is to build its first food factory in Saudi Arabia after signing a contract commiting to the project. The Saudi Press Agency, the country's state news agency, reported that Nestle has signed up for a 117,000 sq m plot in Jeddah's Third Industrial City.
In January 2024, French food group Danone said that it had signed an agreement to sell its premium organic dairy units in the United States to investment firm Platinum Equity. The sale of the Horizon Organic and Wallaby businesses is part of the company's portfolio review and asset rotation program the company announced in March 2022, Danone said in a statement, without disclosing the financial details of the deal.
In December 2023, Kerry Group plc announces it has entered into a definitive agreement to acquire part of the global lactase enzyme business of Chr. Hansen Holding A/S and Novozymes A/S on a carve out basis. This acquisition is subject to European Commission approval of Kerry as a buyer and forms part of the Novozymes and Chr. Hansen merger approval process.